NCT01112592

Brief Summary

We aim to study if pathological NETs formation could be the underlying pathology among patients with recurrent infections and a normal screening of the immune system.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2010

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 27, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 28, 2010

Completed
3 days until next milestone

Study Start

First participant enrolled

May 1, 2010

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

February 27, 2013

Status Verified

March 1, 2012

Enrollment Period

3 years

First QC Date

April 27, 2010

Last Update Submit

February 26, 2013

Conditions

Pyogenic Infections

Keywords

NETsInfectionsNeutrophil function

Outcome Measures

Primary Outcomes (1)

  • Measure NET formation in patients with recurrent infections

    One year

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients are referred subsequent to recurrent, persistent, or unusual infections and after completing preliminary screening of the immune system and ruling out a humoral, cellular or complement immune deficiency.

You may qualify if:

  • Patients with recurrent, persistent, or unusual infections
  • Referred for Neutrophil Functions

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meir Medical Center

Kfar Saba, 44281, Israel

RECRUITING

MeSH Terms

Conditions

Infections

Study Officials

  • Baruch Wolach, MD

    Meir Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ronit Gavrieli, MSc

CONTACT

972-9-7472399ronitgav@clalit.org.il

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2010

First Posted

April 28, 2010

Study Start

May 1, 2010

Primary Completion

May 1, 2013

Study Completion

December 1, 2013

Last Updated

February 27, 2013

Record last verified: 2012-03

Locations

IL(1)